ATLANTA, Oct. 20, 2021 /PRNewswire/ -- CryoLife, Inc.
(NYSE: CRY), a leading cardiac and vascular surgery company focused
on aortic disease, announced today that third quarter 2021
financial results will be released on Thursday, November 4, 2021 after the market
closes. On that day, the Company will hold a teleconference call
and live webcast at 4:30 p.m. ET to
discuss the results, followed by a question and answer session
hosted by Pat Mackin, Chairman,
President and Chief Executive Officer of CryoLife, Inc.
To participate in the conference call dial 862-298-0702 a few
minutes prior to 4:30 p.m. ET. An
audio replay will be available November 4
through November 11, 2021 and can be accessed by dialing
(toll free) 877-660-6853 or 201-612-7415. The conference number for
the replay is 13724263.
The live webcast and replay can be accessed on the Investor
Relations section of the CryoLife website at www.cryolife.com and
selecting Webcasts & Presentations. In addition, a copy of the
earnings press release, which will contain financial and
statistical information for the completed quarter and full year,
can be accessed in the Investor Relations section of the CryoLife
website.
About CryoLife, Inc.
Headquartered in suburban Atlanta,
Georgia, CryoLife is a leader in the manufacturing,
processing, and distribution of medical devices and implantable
tissues used in cardiac and vascular surgical procedures focused on
aortic repair. CryoLife markets and sells products in more than 100
countries worldwide. For additional information about CryoLife,
visit our website, www.cryolife.com.
Contacts:
|
|
|
|
CryoLife
|
Gilmartin Group
LLC
|
D. Ashley
Lee
|
Brian Johnston / Lynn
Lewis
|
Executive Vice
President, Chief Financial Officer
and Chief Operating Officer
|
Phone:
631-807-1986
|
Phone:
770-419-3355
|
investors@cryolife.com
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cryolife-announces-release-date-and-teleconference-call-details-for-third-quarter-2021-financial-results-301404946.html
SOURCE CryoLife, Inc.